Day: January 24, 2025

NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR DISSEMINATION IN THE U.S. THE PROSPECTUS SUPPLEMENT, THE CORRESPONDING BASE SHELF PROSPECTUS AND ANY AMENDMENT TO THE DOCUMENTS ARE ACCESSIBLE THROUGH SEDAR+ QUEBEC CITY, Jan. 23, 2025 (GLOBE NEWSWIRE) — Robex Resources Inc. (TSXV: RBX) (“Robex” or the “Company”) is pleased to announce that it has filed a prospectus supplement (the “Supplement”) to its short form base shelf prospectus dated July 20, 2023 (the “Base Shelf Prospectus”) with respect to its previously announced “best efforts” public offering of 14,634,200 common shares of the Company (each, a “Common Shares”) at a price of $2.05 per Common Share for gross proceeds of $30,000,110 (the “Offering”). All currency amounts in this news release are stated in Canadian dollars, unless otherwise indicated. The Supplement has...

The RealPongCoin or $PONG is using Atari’s registered trademark without Atari’s consent or approval and the company has no affiliation with the crypto project NEW YORK, Jan. 23, 2025 (GLOBE NEWSWIRE) — Atari® — has today announced that RealPongCoin or $PONG is using Atari’s registered PONG trademark without Atari’s consent or approval and the company has no affiliation with the crypto project. Atari is warning the public that RealPongCoin risks deceiving consumers by suggesting an affiliation with Atari, and that Atari’s legal team is actively reviewing measures to stop the misuse of its intellectual property. About Atari Atari is an interactive entertainment company and an iconic gaming industry brand that transcends generations and audiences. The company is globally recognized for its multi-platform, interactive entertainment,...

VANCOUVER, British Columbia, Jan. 23, 2025 (GLOBE NEWSWIRE) — B2Gold Corp. (TSX: BTO, NYSE AMERICAN: BTG, NSX: B2G) (“B2Gold” or the “Company”) announces that it has priced its previously announced offering of convertible senior unsecured notes due 2030 (the “Notes”) in an aggregate principal amount of US$400 million (the “Offering”). The Company has granted the initial purchasers of the Notes an option for a period of 15 days to purchase up to an additional US$60 million aggregate principal amount of Notes. The Notes will bear cash interest semi-annually at a rate of 2.75% per annum. The initial conversion rate for the Notes will be 315.2088 common shares of B2Gold (“Shares”) per US$1,000 principal amount of Notes, equivalent to an initial conversion price of approximately US$3.17 per Share. The initial conversion rate represents...

CALGARY, Alberta, Jan. 23, 2025 (GLOBE NEWSWIRE) — Prospera Energy Inc. (TSX.V: PEI, OTC: GXRFF) (“Prospera“, “PEI” or the “Corporation“) Loan Amendment UpdateThe Corporation is pleased to announce the amendment of its $12,200,000 promissory note, originally dated July 7th, 2024, in collaboration with its principal lender. As part of this amendment, an additional $750,000 has been added to the principal balance, increasing the total to $12,950,000 as of January 23rd, 2025. The original terms of the note remain unchanged, including a 12% interest rate and a two-year maturity period. This amendment is subject to TSXV acceptance. The proceeds from the increased loan will be utilized to execute a twelve to fifteen-well workover program in Prospera’s Heart’s Hill and Luseland properties. This program targets...

WARREN, N.J., Jan. 23, 2025 (GLOBE NEWSWIRE) — Tevogen Bio Holdings Inc. (“Company” or “Tevogen Bio”) (Nasdaq: TVGN), a clinical-stage specialty immunotherapy biotech developing off-the-shelf, genetically unmodified T-cell therapeutics for infectious diseases and cancers, today announced key insights from its recent fireside chat during the J.P. Morgan Healthcare Conference. Utilizing artificial intelligence (AI) and machine learning (ML) has been critical for Tevogen Bio, given its core commitment to patient equity. By applying ML through Tevogen.AI, the company has already achieved notable cost and time efficiencies, developments that could translate directly into savings for patients. The discussion featured Dr. David Rhew, Global Chief Medical Officer & VP of Healthcare at Microsoft (Nasdaq: MSFT), and Mittul Mehta, Chief...